RxDoctor Payments Data

James Stephens, DO

Pain Medicine · Norman, OKNPI 1235459413

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $10,297 and has fallen 80.1% since, to $2,053 in 2025. Among pain medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,116in general payments, 2019–2025

Across 355 payments — averaging $110.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$9K
  • Vertiflex, Inc.$9K
  • Boston Scientific$8K
  • Southern Spine, LLC$5K
  • Nevro Corp.$1K
  • Abbott$888
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$17,75045%
  • Speaking & faculty fees$9,37524%
  • Travel & lodging$2,2806%
  • Food & beverage$9,69625%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,116 in reported general payments places this provider in the 95th percentile of 68 pain medicine providers in Oklahoma.

See all pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$801,057
Medicare patients
474
Services billed
12,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen440$176,579
Nucynta ErTapentadol Hcl39$54,646
BelbucaBuprenorphine Hcl62$52,906
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,009$29,213
Xtampza ErOxycodone Myristate30$12,250
MovantikNaloxegol Oxalate16$7,090
SymproicNaldemedine Tosylate13$5,916
Buprenorphine21$5,774
Gabapentin340$4,400
Pregabalin216$4,394
Morphine Sulfate ErMorphine Sulfate187$4,256
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$2,413
Tizanidine Hcl214$2,350
Diclofenac Sodium110$1,538
Oxycodone Hcl84$1,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er$285$119,803131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 pain medicine providers in Oklahoma.

Other pain medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →